MedKoo Cat#: 315261 | Name: Teicoplanin complex
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Teicoplanin is an antibiotic used in the prophylaxis and treatment of serious infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. It is a glycopeptide antiobiotic extracted from Actinoplanes teichomyceticus, with a similar spectrum of activity to vancomycin. Its mechanism of action is to inhibit bacterial cell wall synthesis. Teicoplanin is marketed by Sanofi-Aventis under the trade name Targocid. Oral teicoplanin has been demonstrated to be effective in the treatment of pseudomembranous colitis and Clostridium difficile-associated diarrhoea, with comparable efficacy with vancomycin.

Chemical Structure

Teicoplanin complex
Teicoplanin complex
CAS#61036-62-2 (complex)

Theoretical Analysis

MedKoo Cat#: 315261

Name: Teicoplanin complex

CAS#: 61036-62-2 (complex)

Chemical Formula: C78H77Cl2N8O32

Exact Mass: 1707.4021

Molecular Weight: 1709.39

Elemental Analysis: C, 54.81; H, 4.54; Cl, 4.15; N, 6.56; O, 29.95

Price and Availability

Size Price Availability Quantity
100mg USD 450.00 2 Weeks
200mg USD 750.00 2 Weeks
500mg USD 1,650.00 2 Weeks
1g USD 2,950.00 2 Weeks
2g USD 5,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
Telicoplanin Ristomycin A.
IUPAC/Chemical Name
34-O-[2-(acetylamino)-2-deoxy-.beta.-D-glucopyranosyl]-22,31-dichloro-7-demethyl-64-O-demethyl-19-deoxy-56-O-[2-deoxy-2-[(8-methyl-1-oxononyl)amino]-.beta.-D-glucopyranosyl]-42-O-.alpha.-D-mannopyranosyl-
InChi Key
BJNLLBUOHPVGFT-CAYRISATSA-N
InChi Code
InChI=1S/C88H97Cl2N9O33/c1-3-4-5-6-7-8-9-10-60(108)94-68-74(113)71(110)58(32-101)129-87(68)132-78-55-26-40-27-56(78)126-52-18-14-38(24-47(52)90)77(131-86-67(92-34(2)103)73(112)70(109)57(31-100)128-86)69-84(121)98-66(85(122)123)45-29-42(105)30-54(127-88-76(115)75(114)72(111)59(33-102)130-88)61(45)44-23-37(13-15-49(44)106)63(81(118)99-69)96-83(120)65(40)97-82(119)64-39-21-41(104)28-43(22-39)124-53-25-36(12-16-50(53)107)62(91)80(117)93-48(79(116)95-64)20-35-11-17-51(125-55)46(89)19-35/h11-19,21-30,48,57-59,62-77,86-88,100-102,104-107,109-115H,3-10,20,31-33,91H2,1-2H3,(H,92,103)(H,93,117)(H,94,108)(H,95,116)(H,96,120)(H,97,119)(H,98,121)(H,99,118)(H,122,123)/t48-,57-,58-,59-,62-,63-,64+,65-,66+,67-,68-,69+,70-,71-,72-,73-,74-,75+,76+,77-,86+,87+,88?/m1/s1
SMILES Code
CCCCCCCCC/C(O)=N/[C@]([C@@](OC1=C2C=C([C@](/N=C(O)\[C@](/N=C(O)/[C@@](/N=C(O)\[C@@](N)([H])C3=CC4=C(O)C=C3)([H])CC5=CC(Cl)=C(O2)C=C5)([H])C6=CC(O)=CC(O4)=C6)([H])/C(O)=N/[C@](/C(O)=N/7)([H])C8=CC(C9=C([C@@]%10([H])C(O)=O)C=C(O)C=C9OC%11([H])[C@](O)([H])[C@](O)([H])[C@@](O)([H])[C@@](O%11)([H])CO)=C(O)C=C8)C=C1OC%12=C(Cl)C=C([C@](O[C@@]%13([H])[C@@](/N=C(O)/C)([H])[C@](O)([H])[C@@](O)([H])[C@@](O%13)([H])CO)([H])[C@@]7([H])/C(O)=N/%10)C=C%12)([H])O%14)([H])[C@](O)([H])[C@@](O)([H])[C@@]%14([H])CO
Appearance
Solid powder
Purity
95%
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO.
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,709.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mellere L, Bava A, Capozzoli C, Branduardi P, Berini F, Beltrametti F. Strain Improvement and Strain Maintenance Revisited. The Use of Actinoplanes teichomyceticus ATCC 31121 Protoplasts in the Identification of Candidates for Enhanced Teicoplanin Production. Antibiotics (Basel). 2021 Dec 27;11(1):24. doi: 10.3390/antibiotics11010024. PMID: 35052901; PMCID: PMC8773182. 2: Tengattini S, Corana F, Bianchi D, Marrubini G, Colombo R, Furlanetto S, Terreni M, Temporini C. Application of an HPLC-MS/MS method for Teicoplanin drug substance and related impurities, part 2: Identity assignment of related impurities. J Pharm Biomed Anal. 2019 May 10;168:38-43. doi: 10.1016/j.jpba.2019.02.017. Epub 2019 Feb 13. PMID: 30784888. 3: Han S, Le BV, Hajare HS, Baxter RH, Miller SJ. X-ray crystal structure of teicoplanin A₂-2 bound to a catalytic peptide sequence via the carrier protein strategy. J Org Chem. 2014 Sep 19;79(18):8550-6. doi: 10.1021/jo501625f. Epub 2014 Sep 2. PMID: 25147913; PMCID: PMC4168787. 4: Yoshida M, Matzno S, Namba H, Nishikata M, Matsuyama K. Statistical analysis of the adverse effects of glycopeptide antibiotics, based on pharmacokinetics and toxicokinetics (PK/TK). J Infect Chemother. 2006 Jun;12(3):114-8. doi: 10.1007/s10156-006-0437-z. PMID: 16826342. 5: Berthod A, Valleix A, Tizon V, Leonce E, Caussignac C, Armstrong DW. Retention and selectivity of teicoplanin stationary phases after copper complexation and isotopic exchange. Anal Chem. 2001 Nov 15;73(22):5499-508. doi: 10.1021/ac010444t. PMID: 11816580. 6: Quarta C, Borghi A, Zerilli LF, De Pietro MT, Ferrari P, Trani A, Lancini GC. Isolation and structure determination of a novel complex of the teicoplanin family. J Antibiot (Tokyo). 1996 Jul;49(7):644-50. doi: 10.7164/antibiotics.49.644. PMID: 8784424. 7: Borghi A, Ferrari P, Gallo GG, Zanol M, Zerilli LF, Lancini GC. Microbial de- mannosylation and mannosylation of teicoplanin derivatives. J Antibiot (Tokyo). 1991 Dec;44(12):1444-51. doi: 10.7164/antibiotics.44.1444. PMID: 1838104. 8: Jones RN, Goldstein FW, Zhou XY. Activities of two new teicoplanin amide derivatives (MDL 62211 and MDL 62873) compared with activities of teicoplanin and vancomycin against 800 recent staphylococcal isolates from France and the United States. Antimicrob Agents Chemother. 1991 Mar;35(3):584-6. doi: 10.1128/AAC.35.3.584. PMID: 1828137; PMCID: PMC245056. 9: Zerilli LF, Cavenaghi L, Bernareggi A, Assandri A. Teicoplanin metabolism in rats. Antimicrob Agents Chemother. 1989 Oct;33(10):1791-4. doi: 10.1128/AAC.33.10.1791. PMID: 2531569; PMCID: PMC172756. 10: Cometti A, Gallo GG, Kettenring J, Panzone GB, Tuan G, Zerilli LF. Isolation and structure determination of the main related substances of teicoplanin, a glycopeptide antibiotic. Farmaco Sci. 1988 Dec;43(12):1005-18. PMID: 2977757. 11: Joos B, Lüthy R. Determination of teicoplanin concentrations in serum by high-pressure liquid chromatography. Antimicrob Agents Chemother. 1987 Aug;31(8):1222-4. doi: 10.1128/AAC.31.8.1222. PMID: 2957953; PMCID: PMC174907.